Brevan Howard Capital Management’s Treace Medical Concepts TMCI Stock Holding History

Brevan Howard Capital Management’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,919	Closed	-$207K	–	2278
2025 Q3	$207K	Sell	30,919 -20,959	-40%	-$137K	﹤0.01%	1735
2025 Q2	$305K	Buy	51,878 +11,634	+29%	+$75.8K	﹤0.01%	1542
2025 Q1	$338K	Buy	40,244 +26,848	+200%	+$241K	﹤0.01%	830
2024 Q4	$99.7K	Buy	+13,396	New	+$89.6K	﹤0.01%	967
2024 Q3	–	Sell	-26,241	Closed	-$175K	–	1437
2024 Q2	$175K	Buy	+26,241	New	+$212K	﹤0.01%	919

Other funds holding TMCI

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Brevan Howard Capital Management's TMCI Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Treace Medical Concepts (TMCI) in Q4 2025, closing a stake of 30,919 shares — an estimated $207K sold.

Brevan Howard Capital Management first reported a position in TMCI in Q2 2024 and held it in 5 quarters. The position peaked at $338K in Q1 2025. 115 funds tracked by Wall St. Rank hold TMCI as of Q4 2025.

Brevan Howard Capital Management reported no remaining Treace Medical Concepts position as of Q4 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 30,919 Treace Medical Concepts shares in Q4 2025, an estimated $207K.
Brevan Howard Capital Management first reported a position in Treace Medical Concepts in Q2 2024 and held it in 5 quarters.
Brevan Howard Capital Management's Treace Medical Concepts position peaked at $338K in Q1 2025.
115 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.